RESUMEN
Immunotherapy has been shown to be highly effective in some types of cancer caused by viruses. Gene therapy involves insertion or modification of a therapeutic gene, to correct for inappropriate gene products that cause/may cause diseases. Both these types of therapy have been used as alternative ways to avoid cancers caused by oncoviruses. In this review, we summarize recent studies on immunotherapy and gene therapy including the topics of oncolytic immunotherapy, immune checkpoint inhibitors, gene replacement, antisense oligonucleotides, RNA interference, clustered regularly interspaced short palindromic repeats Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing, transcription activator-like effector nucleases (TALENs) and custom treatment for Epstein-Barr virus, human T-lymphotropic virus 1, hepatitis B virus, human papillomavirus, hepatitis C virus, herpesvirus associated with Kaposi's sarcoma, Merkel cell polyomavirus, and cytomegalovirus.
Asunto(s)
Terapia Genética , Inmunoterapia , Infecciones por Retroviridae/terapia , Retroviridae/fisiología , Animales , Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Espaciadas , Edición Génica , Humanos , Retroviridae/genética , Infecciones por Retroviridae/genética , Infecciones por Retroviridae/inmunología , Infecciones por Retroviridae/virologíaRESUMEN
PD-1-targeted therapies have shown modest antiviral effects in preclinical models of chronic viral infection. Thus, novel therapy protocols are necessary to enhance T cell immunity and viral control to overcome T cell dysfunction and immunosuppression. Here, we demonstrate that nanoparticle-based therapeutic vaccination improved PD-1-targeted therapy during chronic infection with Friend retrovirus (FV). Prevention of inhibitory signals by blocking PD-L1 in combination with therapeutic vaccination with nanoparticles containing the microbial compound CpG and a CD8+ T cell Gag epitope peptide synergistically enhanced functional virus-specific CD8+ T cell responses and improved viral clearance. We characterized the CD8+ T cell populations that were affected by this combination therapy, demonstrating that new effector cells were generated and that exhausted CD8+ T cells were reactivated at the same time. While CD8+ T cells with high PD-1 (PD-1hi) expression turned into a large population of granzyme B-expressing CD8+ T cells after combination therapy, CXCR5-expressing follicular cytotoxic CD8+ T cells also expanded to a high degree. Thus, our study describes a very efficient approach to enhance virus control and may help us to understand the mechanisms of combination immunotherapy reactivating CD8+ T cell immunity. A better understanding of CD8+ T cell immunity during combination therapy will be important for developing efficient checkpoint therapies against chronic viral infections and cancer.IMPORTANCE Despite significant efforts, vaccines are not yet available for every infectious pathogen, and the search for a protective approach to prevent the establishment of chronic infections, i.e., with HIV, continues. Immune checkpoint therapies targeting inhibitory receptors, such as PD-1, have shown impressive results against solid tumors. However, immune checkpoint therapies have not yet been licensed to treat chronic viral infections, since a blockade of inhibitory receptors alone provides only limited benefit, as demonstrated in preclinical models of chronic viral infection. Thus, there is a high interest in the development of potent combination immunotherapies. Here, we tested whether the combination of a PD-L1 blockade and therapeutic vaccination with functionalized nanoparticles is a potent therapy during chronic Friend retrovirus infection. We demonstrate that the combination therapy induced a synergistic reinvigoration of the exhausted virus-specific CD8+ T cell immunity. Taken together, our results provide further information on how to improve PD-1-targeted therapies during chronic viral infection and cancer.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Virus de la Leucemia Murina de Friend/inmunología , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Activación de Linfocitos , Infecciones por Retroviridae/terapia , Vacunación , Animales , Células Cultivadas , Femenino , Ratones , Ratones Endogámicos C57BL , Receptores CXCR5/análisis , Infecciones por Retroviridae/inmunologíaRESUMEN
The iconic Australian marsupial, the koala (Phascolarctos cinereus), has suffered dramatic population declines as a result of habitat loss and fragmentation, disease, vehicle collision mortality, dog attacks, bushfires and climate change. In 2012, koalas were officially declared vulnerable by the Australian government and listed as a threatened species. In response, research into diseases affecting koalas has expanded rapidly. The two major pathogens affecting koalas are Chlamydia pecorum, leading to chlamydial disease and koala retrovirus (KoRV). In the last eight years, these pathogens and their diseases have received focused study regarding their sources, genetics, prevalence, disease presentation and transmission. This has led to vast improvements in pathogen detection and treatment, including the ongoing development of vaccines for each as a management and control strategy. This review will summarize and highlight the important advances made in understanding and combating C. pecorum and KoRV in koalas, since they were declared a threatened species. With complementary advances having also been made from the koala genome sequence and in our understanding of the koala immune system, we are primed to make a significant positive impact on koala health into the future.
Asunto(s)
Infecciones por Chlamydia/veterinaria , Phascolarctidae/inmunología , Infecciones por Retroviridae/veterinaria , Animales , Australia , Chlamydia , Infecciones por Chlamydia/diagnóstico , Infecciones por Chlamydia/prevención & control , Infecciones por Chlamydia/terapia , Especies en Peligro de Extinción , Phascolarctidae/microbiología , Phascolarctidae/virología , Retroviridae , Infecciones por Retroviridae/diagnóstico , Infecciones por Retroviridae/prevención & control , Infecciones por Retroviridae/terapia , Vacunas ViralesRESUMEN
CLINICAL IMPORTANCE: Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections are found in cats worldwide. Both infections are associated with a variety of clinical signs and can impact quality of life and longevity. SCOPE: This document is an update of the 2008 American Association of Feline Practitioners' feline retrovirus management guidelines and represents current knowledge on pathogenesis, diagnosis, prevention and treatment of retrovirus infections in cats. TESTING AND INTERPRETATION: Although vaccines are available for FeLV in many countries and for FIV in some countries, identification of infected cats remains an important factor for preventing new infections. The retrovirus status of every cat at risk of infection should be known. Cats should be tested as soon as possible after they are acquired, following exposure to an infected cat or a cat of unknown infection status, prior to vaccination against FeLV or FIV, and whenever clinical illness occurs. It might not be possible to determine a cat's infection status based on testing at a single point in time; repeat testing using different methods could be required. Although FeLV and FIV infections can be associated with clinical disease, some infected cats, especially those infected with FIV, can live for many years with good quality of life. MANAGEMENT OF INFECTED CATS: There is a paucity of data evaluating treatments for infected cats, especially antiretroviral and immunomodulatory drugs. Management of infected cats is focused on effective preventive healthcare strategies, and prompt identification and treatment of illness, as well as limiting the spread of infection.
Asunto(s)
Enfermedades de los Gatos , Infecciones por Retroviridae , Animales , Enfermedades de los Gatos/diagnóstico , Enfermedades de los Gatos/terapia , Gatos , Infecciones por Retroviridae/diagnóstico , Infecciones por Retroviridae/terapia , Infecciones por Retroviridae/veterinaria , Medicina Veterinaria/organización & administraciónAsunto(s)
Anticuerpos Neutralizantes/uso terapéutico , Infecciones por Retroviridae/terapia , Virus Espumoso de los Simios/inmunología , Zoonosis/terapia , Zoonosis/virología , Animales , Anticuerpos Neutralizantes/química , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/química , Anticuerpos Antivirales/uso terapéutico , Mapeo Epitopo , Humanos , Inmunización Pasiva/métodos , Infecciones por Retroviridae/epidemiología , Infecciones por Retroviridae/inmunología , Infecciones por Retroviridae/virología , Virus Espumoso de los Simios/genética , Vacunas Virales/uso terapéutico , Zoonosis/sangre , Zoonosis/epidemiologíaRESUMEN
Approximately 4.4% of the human genome is comprised of endogenous retroviral sequences, a record of an evolutionary battle between man and retroviruses. Much of what we know about viral immunity comes from studies using mouse models. Experiments using the Friend virus (FV) model have been particularly informative in defining highly complex anti-retroviral mechanisms of the intrinsic, innate and adaptive arms of immunity. FV studies have unraveled fundamental principles about how the immune system controls both acute and chronic viral infections. They led to a more complete understanding of retroviral immunity that begins with cellular sensing, production of type I interferons, and the induction of intrinsic restriction factors. Novel mechanisms have been revealed, which demonstrate that these earliest responses affect not only virus replication, but also subsequent innate and adaptive immunity. This review on FV immunity not only surveys the complex host responses to a retroviral infection from acute infection to chronicity, but also highlights the many feedback mechanisms that regulate and counter-regulate the various arms of the immune system. In addition, the discovery of molecular mechanisms of immunity in this model have led to therapeutic interventions with implications for HIV cure and vaccine development.
Asunto(s)
Inmunidad Adaptativa , Virus de la Leucemia Murina de Friend/inmunología , Interacciones Microbiota-Huesped/inmunología , Inmunidad Innata , Infecciones por Retroviridae/inmunología , Animales , Antirretrovirales/uso terapéutico , Humanos , Inmunoterapia , Ratones , Infecciones por Retroviridae/tratamiento farmacológico , Infecciones por Retroviridae/terapiaRESUMEN
The 12th International Foamy Virus Conference took place on August 30â»31, 2018 at the Technische Universität Dresden, Dresden, Germany. The meeting included presentations on current research on non-human primate and non-primate foamy viruses (FVs; also called spumaretroviruses) as well as keynote talks on related research areas in retroviruses. The taxonomy of foamy viruses was updated earlier this year to create five new genera in the subfamily, Spumaretrovirinae, based on their animal hosts. Research on viruses from different genera was presented on topics of potential relevance to human health, such as natural infections and cross-species transmission, replication, and viral-host interactions in particular with the immune system, dual retrovirus infections, virus structure and biology, and viral vectors for gene therapy. This article provides an overview of the current state-of-the-field, summarizes the meeting highlights, and presents some important questions that need to be addressed in the future.
Asunto(s)
Terapia Genética , Infecciones por Retroviridae , Spumavirus/clasificación , Animales , Vectores Genéticos , Alemania , Humanos , Primates , Investigación , Infecciones por Retroviridae/inmunología , Infecciones por Retroviridae/terapia , Spumavirus/patogenicidad , Replicación ViralRESUMEN
Tight regulation of immune responses is not only critical for preventing autoimmune diseases but also for preventing immunopathological damage during infections in which overactive immune responses may be more harmful for the host than the pathogen itself. Regulatory T cells (Tregs) play a critical role in this regulation, which was discovered using the Friend retrovirus (FV) mouse model. Subsequent FV studies revealed basic biological information about Tregs, including their suppressive activity on effector cells as well as the molecular mechanisms of virus-induced Treg expansion. Treg suppression not only limits immunopathology but also prevents complete elimination of pathogens contributing to chronic infections. Therefore, Tregs play a complex role in the pathogenesis of persistent retroviral infections. New therapeutic concepts to reactivate effector T-cell responses in chronic viral infections by manipulating Tregs also came from work with the FV model. This knowledge initiated many studies to characterize the role of Tregs in HIV pathogenesis in humans, where a complex picture is emerging. On one hand, Tregs suppress HIV-specific effector T-cell responses and are themselves targets of infection, but on the other hand, Tregs suppress HIV-induced immune hyperactivation and thus slow the infection of conventional CD4+ T cells and limit immunopathology. In this review, the basic findings from the FV mouse model are put into perspective with clinical and basic research from HIV studies. In addition, the few Treg studies performed in the simian immunodeficiency virus (SIV) monkey model will also be discussed. The review provides a comprehensive picture of the diverse role of Tregs in different retroviral infections and possible therapeutic approaches to treat retroviral chronicity and pathogenesis by manipulating Treg responses.
Asunto(s)
Interacciones Huésped-Patógeno , Modelos Inmunológicos , Infecciones por Retroviridae/inmunología , Retroviridae/inmunología , Linfocitos T Reguladores/inmunología , Animales , Humanos , Tolerancia Inmunológica , Terapia de Inmunosupresión , Linfopoyesis , Retroviridae/fisiología , Infecciones por Retroviridae/patología , Infecciones por Retroviridae/terapia , Infecciones por Retroviridae/virología , Linfocitos T Reguladores/patología , Linfocitos T Reguladores/virologíaRESUMEN
BACKGROUND Morphea, also known as localized scleroderma, is a rare autoimmune connective tissue disease characterized by skin fibrosis. UVA1 phototherapy is an important asset in the reduction of clinical manifestations in morphea. There are studies claiming that UV light modulates the expression of some human endogenous retroviral sequences. The aim of this study was to determine if the expression of HERV-K10 gag element is lowered by UVA1 phototherapy in morphea, a disease in which such irradiation has a soothing effect. MATERIAL AND METHODS The expression levels of the HERV-K10 gag were assessed by real-time PCR (polymerase chain reaction) in peripheral blood mononuclear cells (PBMC) and skin-punch biopsies of healthy volunteers and 9 morphea patients before and after phototherapy. Additionally, correlations between the HERV-K10 gag expression and age, disease duration, the Localized Scleroderma Skin Severity Index (LoSSI), and antinuclear antibody (ANA) titers were assessed. RESULTS In PBMC, HERV-K10 gag mRNA was significantly elevated after UVA1 phototherapy compared to healthy controls. Most of the patients responded with an increased expression level of this sequence. However, we found no statistical evidence at this point that phototherapy indeed has an effect on the HERV-K10 gag expression (there were no statistical differences in PBMC of morphea patients before and after phototherapy). Similarly, there was no statistically relevant effect of the UVA1 on the expression of HERV-K10 gag in skin. CONCLUSIONS At this point, the effect of UVA1 phototherapy on the expression of HERV-K10 gag cannot be statistically confirmed.
Asunto(s)
Retrovirus Endógenos/efectos de la radiación , Productos del Gen gag/biosíntesis , Infecciones por Retroviridae/terapia , Esclerodermia Localizada/terapia , Terapia Ultravioleta/métodos , Adulto , Anciano , Estudios de Casos y Controles , Retrovirus Endógenos/genética , Retrovirus Endógenos/metabolismo , Femenino , Productos del Gen gag/genética , Productos del Gen gag/metabolismo , Humanos , Leucocitos Mononucleares/efectos de la radiación , Masculino , Persona de Mediana Edad , ARN Mensajero/genética , Reacción en Cadena en Tiempo Real de la Polimerasa , Infecciones por Retroviridae/sangre , Infecciones por Retroviridae/patología , Infecciones por Retroviridae/virología , Esclerodermia Localizada/sangre , Esclerodermia Localizada/patología , Esclerodermia Localizada/virología , Rayos UltravioletaRESUMEN
Integration is a key feature of the retroviral life cycle. This process involves packaging of the viral genome into chromatin, which is often assumed to occur as a post-integration step. In this issue of Cell Host & Microbe, Wang and colleagues (Wang et al., 2016) show that chromatinization occurs before integration, raising new questions about the role of histones in retroviral integration and transcription.
Asunto(s)
Retroviridae/crecimiento & desarrollo , Retroviridae/genética , Ensamble de Virus , Integración Viral/genética , Acetilación , Animales , Proteínas de la Cápside/metabolismo , Línea Celular Tumoral , Cromatina/genética , Cromatina/virología , ADN Viral/genética , ADN Viral/fisiología , Células Madre de Carcinoma Embrionario/virología , Epigenómica , Fibroblastos , Regulación Viral de la Expresión Génica , Histonas/metabolismo , Histonas/fisiología , Humanos , Infecciones/metabolismo , Estadios del Ciclo de Vida , Ratones , Células Madre Embrionarias de Ratones/virología , Proteínas de la Nucleocápside/metabolismo , Infecciones por Retroviridae/terapia , Infecciones por Retroviridae/virología , Transcripción Genética , Integración Viral/fisiologíaRESUMEN
Natural killer (NK) cells belong to the innate immune system and protect against cancers and a variety of viruses including retroviruses by killing transformed or infected cells. They express activating and inhibitory receptors on their cell surface and often become activated after recognizing virus-infected cells. They have diverse antiviral effector functions like the release of cytotoxic granules, cytokine production and antibody dependent cellular cytotoxicity. The importance of NK cell activity in retroviral infections became evident due to the discovery of several viral strategies to escape recognition and elimination by NK cells. Mutational sequence polymorphisms as well as modulation of surface receptors and their ligands are mechanisms of the human immunodeficiency virus-1 to evade NK cell-mediated immune pressure. In Friend retrovirus infected mice the virus can manipulate molecular or cellular immune factors that in turn suppress the NK cell response. In this model NK cells lack cytokines for optimal activation and can be functionally suppressed by regulatory T cells. However, these inhibitory pathways can be overcome therapeutically to achieve full activation of NK cell responses and ultimately control dissemination of retroviral infection. One effective approach is to modulate the crosstalk between NK cells and dendritic cells, which produce NK cell-stimulating cytokines like type I interferons (IFN), IL-12, IL-15, and IL-18 upon retrovirus sensing or infection. Therapeutic administration of IFNα directly increases NK cell killing of retrovirus-infected cells. In addition, IL-2/anti-IL-2 complexes that direct IL-2 to NK cells have been shown to significantly improve control of retroviral infection by NK cells in vivo. In this review, we describe novel approaches to improve NK cell effector functions in retroviral infections. Immunotherapies that target NK cells of patients suffering from viral infections might be a promising treatment option for the future.
Asunto(s)
Células Asesinas Naturales/inmunología , Infecciones por Retroviridae/inmunología , Infecciones por Retroviridae/terapia , Retroviridae/inmunología , Animales , Células Dendríticas/inmunología , Humanos , Inmunoterapia/métodos , Interferón-alfa/uso terapéutico , Interleucina-2/uso terapéutico , Células Asesinas Naturales/fisiología , Ratones , Retroviridae/fisiología , Infecciones por Retroviridae/prevención & control , Infecciones por Retroviridae/virologíaRESUMEN
BACKGROUND: Regulatory T cells (Tregs) have been shown to limit anti-viral immunity during chronic retroviral infection and to restrict vaccine-induced T cell responses. The objective of the study was to assess whether a combinational therapy of nanoparticle-based therapeutic vaccination and concomitant transient ablation of Tregs augments anti-viral immunity and improves virus control in chronically retrovirus-infected mice. Therefore, chronically Friend retrovirus (FV)-infected mice were immunized with calcium phosphate (CaP) nanoparticles functionalized with TLR9 ligand CpG and CD8(+) or CD4(+) T cell epitope peptides (GagL85-93 or Env gp70123-141) of FV. In addition, Tregs were ablated during the immunization process. Reactivation of CD4(+) and CD8(+) effector T cells was analysed and the viral loads were determined. RESULTS: Therapeutic vaccination of chronically FV-infected mice with functionalized CaP nanoparticles transiently reactivated cytotoxic CD8(+) T cells and significantly reduced the viral loads. Transient ablation of Tregs during nanoparticle-based therapeutic vaccination strongly enhanced anti-viral immunity and further decreased viral burden. CONCLUSION: Our data illustrate a crucial role for CD4(+) Foxp3(+) Tregs in the suppression of anti-viral T cell responses during therapeutic vaccination against chronic retroviral infection. Thus, the combination of transient Treg ablation and therapeutic nanoparticle-based vaccination confers robust and sustained anti-viral immunity.
Asunto(s)
Leucemia Experimental/terapia , Procedimientos de Reducción del Leucocitos , Nanopartículas/administración & dosificación , Infecciones por Retroviridae/terapia , Linfocitos T Reguladores/inmunología , Infecciones Tumorales por Virus/terapia , Vacunas Virales/administración & dosificación , Animales , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Terapia Combinada/métodos , Virus de la Leucemia Murina de Friend/inmunología , Leucemia Experimental/inmunología , Ratones Endogámicos C57BL , Infecciones por Retroviridae/inmunología , Resultado del Tratamiento , Infecciones Tumorales por Virus/inmunologíaRESUMEN
Several lines of evidence indicate that the sympathetic nervous system (SNS) might be involved in the pathogenesis and progression of retroviral infections. However, experimental data are scarce and findings inconsistent. Here, we investigated the role of the SNS during acute infection with Friend virus (FV), a pathogenic murine retrovirus that causes polyclonal proliferation of erythroid precursor cells and splenomegaly in adult mice. Experimental animals were infected with FV complex, and viral load, spleen weight, and splenic noradrenaline (NA) concentration was analyzed until 25 days post infection. Results show that FV infection caused a massive but transient depletion in splenic NA during the acute phase of the disease. At the peak of the virus-induced splenomegaly, splenic NA concentration was reduced by about 90% compared to naïve uninfected mice. Concurrently, expression of the catecholamine degrading enzymes monoamine oxidase A (MAO-A) and catechol-O-methyltransferase (COMT) was significantly upregulated in immune cells of the spleen. Pharmacological inhibition of MAO-A and COMT by the selective inhibitors clorgyline and 3,5-dinitrocatechol, respectively, efficiently blocked NA degradation and significantly reduced viral load and virus-induced splenomegaly. In contrast, chemical sympathectomy prior to FV inoculation aggravated the acute infection and extended the duration of the disease. Together these findings demonstrate that catecholamine availability at the site of viral replication is an important factor affecting the course of retroviral infections.
Asunto(s)
Catecolaminas/uso terapéutico , Virus de la Leucemia Murina de Friend/aislamiento & purificación , Infecciones por Retroviridae/terapia , Animales , Catecol O-Metiltransferasa/metabolismo , Catecolaminas/metabolismo , Femenino , Ratones , Ratones Endogámicos C57BL , Monoaminooxidasa/metabolismo , Norepinefrina/metabolismo , Retroviridae , Infecciones por Retroviridae/inmunología , Infecciones por Retroviridae/metabolismo , Infecciones por Retroviridae/virología , Bazo/inmunología , Simpatectomía Química , Sistema Nervioso Simpático/virología , Carga ViralRESUMEN
HIV-1 is the most prevalent retrovirus, with over 30 million people infected worldwide. Nevertheless, infection caused by other human retroviruses like HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4 is gaining importance. Initially confined to specific geographical areas, HIV-2, HTLV-1 and HTLV-2 are becoming a major concern in non-endemic countries due to international migration flows. Clinical manifestations of retroviruses range from asymptomatic carriers to life-threatening conditions, such as AIDS in HIV-2 infection or adult T-cell lymphoma/leukemia or tropical spastic paraparesis in HTLV-1 infection. HIV-2 is naturally resistant to some antiretrovirals frequently used to treat HIV-1 infection, but it does have effective antiretroviral therapy options. Unfortunately, HTLV still has limited therapeutic options. In this article, we will review the epidemiological, clinical, diagnostic, pathogenic and therapeutic aspects of infections caused by these human retroviruses.
Asunto(s)
Infecciones por Retroviridae , Retroviridae/fisiología , Coinfección , Humanos , Prevalencia , Infecciones por Retroviridae/diagnóstico , Infecciones por Retroviridae/epidemiología , Infecciones por Retroviridae/patología , Infecciones por Retroviridae/terapia , Infecciones por Retroviridae/virologíaRESUMEN
Therapeutic vaccinations have a potential application in infections where no curative treatment is available. In contrast to HIV, efficacious vaccines for a cat retrovirus, feline leukemia virus (FeLV), are commercially available. However, the infection is still prevalent, and no effective treatment of the infection is known. By vaccinating persistently FeLV-infected cats and presenting FeLV antigens to the immune system of the host, e.g., in the form of recombinant and/or adjuvanted antigens, we intended to shift the balance toward an advantage of the host so that persistent infection could be overcome by the infected cat. Two commercially available FeLV vaccines efficacious in protecting naïve cats from FeLV infection were tested in six experimentally and persistently FeLV-infected cats: first, a canarypox-vectored vaccine, and second, an adjuvanted, recombinant envelope vaccine was repeatedly administered with the aim to stimulate the immune system. No beneficial effects on p27 antigen and plasma viral RNA loads, anti-FeLV antibodies, or life expectancy of the cats were detected. The cats were unable to overcome or decrease viremia. Some cats developed antibodies to FeLV antigens although not protective. Thus, we cannot recommend vaccinating persistently FeLV-infected cats as a means of improving their FeLV status, quality of life or life expectancy. We suggest testing of all cats for FeLV infection prior to FeLV vaccination.
Asunto(s)
Enfermedades de los Gatos/terapia , Virus de la Leucemia Felina/inmunología , Infecciones por Retroviridae/veterinaria , Proteínas Oncogénicas de Retroviridae/uso terapéutico , Infecciones Tumorales por Virus/veterinaria , Vacunas Sintéticas/uso terapéutico , Vacunas Virales/uso terapéutico , Animales , Anticuerpos Antivirales/inmunología , Enfermedades de los Gatos/virología , Gatos , Productos del Gen gag/sangre , Virus de la Leucemia Felina/patogenicidad , Esperanza de Vida , Calidad de Vida , Infecciones por Retroviridae/terapia , Infecciones por Retroviridae/virología , Proteínas Oncogénicas de Retroviridae/administración & dosificación , Infecciones Tumorales por Virus/terapia , Infecciones Tumorales por Virus/virología , Vacunación/veterinaria , Vacunas Sintéticas/administración & dosificación , Carga Viral , Vacunas Virales/administración & dosificación , Viremia/terapia , Viremia/veterinariaRESUMEN
Squamous skin cancer, which is commonly called squamous cell carcinoma (SCC), represents an immunological puzzle. The major skin cancers (SCC, basal cell carcinoma, Merkel cell carcinoma, and melanoma) and actinic keratosis (AK), as a potential precursor lesion of SCC, are common in immune-suppressed patients. The increased risk of a particular cancer in chronically immune-suppressed patients is a feature of those cancers for which a virus contributes to the aetiology. However, amongst the skin cancers mentioned, a causal virus (Merkel polyomavirus) has been identified only for Merkel tumours. It is therefore reasonable to determine whether a virus or viruses contribute to the risk of the development of AK and SCC. This chapter will first consider the limitations of the methodologies available for determining the roles of viruses in the aetiologies of AK and SCC and review current evidence of the contribution of a virus to the risk of developing these diseases. It will then consider why there might be an increased risk of AK in chronically immune-suppressed patients although no relevant virus can be identified.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Carcinoma de Células Escamosas/virología , Queratosis Actínica/virología , Infecciones por Papillomavirus/complicaciones , Infecciones por Retroviridae/complicaciones , Neoplasias Cutáneas/virología , Vacunas Virales/uso terapéutico , Carcinoma de Células Escamosas/prevención & control , Humanos , Queratosis Actínica/prevención & control , Infecciones por Papillomavirus/terapia , Infecciones por Retroviridae/terapia , Neoplasias Cutáneas/prevención & controlRESUMEN
The 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses was held in Montreal, Québec from June 26th to June 30th, 2013 and was therefore hosted by a Canadian city for the first time. The major topic of the meeting was human T-lymphotropic viruses (HTLVs) and was covered through distinct oral and poster presentation sessions: clinical research, animal models, immunology, molecular and cellular biology, human endogenous and emerging exogenous retroviruses and virology. In this review, highlights of the meeting are provided by different experts for each of these research areas.
Asunto(s)
Interacciones Huésped-Patógeno , Infecciones por Retroviridae/patología , Infecciones por Retroviridae/virología , Retroviridae/inmunología , Retroviridae/fisiología , Animales , Investigación Biomédica/tendencias , Ensayos Clínicos como Asunto , Humanos , Modelos Animales , Infecciones por Retroviridae/diagnóstico , Infecciones por Retroviridae/terapiaRESUMEN
Chronic infections with human viruses, such as HIV and HCV, or mouse viruses, such as LCMV or Friend Virus (FV), result in functional exhaustion of CD8(+) T cells. Two main mechanisms have been described that mediate this exhaustion: expression of inhibitory receptors on CD8(+) T cells and expansion of regulatory T cells (Tregs) that suppress CD8(+) T cell activity. Several studies show that blockage of one of these pathways results in reactivation of CD8(+) T cells and partial reduction in chronic viral loads. Using blocking antibodies against PD-1 ligand and Tim-3 and transgenic mice in which Tregs can be selectively ablated, we compared these two treatment strategies and combined them for the first time in a model of chronic retrovirus infection. Blocking inhibitory receptors was more efficient than transient depletion of Tregs in reactivating exhausted CD8(+) T cells and reducing viral set points. However, a combination therapy was superior to any single treatment and further augmented CD8(+) T cell responses and resulted in a sustained reduction in chronic viral loads. These results demonstrate that Tregs and inhibitory receptors are non-overlapping factors in the maintenance of chronic viral infections and that immunotherapies targeting both pathways may be a promising strategy to treat chronic infectious diseases.
Asunto(s)
Linfocitos T CD8-positivos/inmunología , Receptores Coestimuladores e Inhibidores de Linfocitos T/antagonistas & inhibidores , Activación de Linfocitos , Depleción Linfocítica , Infecciones por Retroviridae/terapia , Linfocitos T Reguladores/inmunología , Animales , Anticuerpos/inmunología , Enfermedad Crónica , Receptores Coestimuladores e Inhibidores de Linfocitos T/inmunología , Femenino , Receptor 2 Celular del Virus de la Hepatitis A , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Ratones Transgénicos , Receptor de Muerte Celular Programada 1/inmunología , Receptores Virales/antagonistas & inhibidores , Receptores Virales/inmunología , Retroviridae/inmunología , Carga Viral , Virus/efectos de los fármacos , Virus/inmunologíaRESUMEN
In the current study, exposure of mammary tumor cells derived from mice transgenic for the polyomavirus middle T oncogene to ionizing radiation resulted in the generation of a tumor cell population that preferentially expressed cancer stem cell markers. In addition, these cells were more resistant to subsequent radiation treatments and appeared to acquire an enhanced capacity for dissemination to the lungs of mice. Therefore, we tested an immunotherapy approach to the treatment of local and disseminated mammary tumor cells in a murine model using a recently developed molecular chaperone-based vaccine that specifically targets the radioresistant subpopulation of tumor cells. Heat shock protein 70-peptide complexes (Hsp70.PC-F) were extracted from fusions of dendritic cells and radiation-enriched tumor cells, and the resulting chaperone vaccines were used to treat mice with pre-existing lung metastases. Immunization of mice with the Hsp70.PC-F vaccine resulted in a T cell-mediated immune response, including a significant increase in CD4 and CD8 T cell proliferation and the induction of effector T cells capable of targeting radioresistant tumor cells. Importantly, the growth of primary tumors was inhibited, and the number of tumor cells metastasizing to lung was reduced significantly by combining chaperone vaccine with radiotherapy. These results indicate that Hsp70.PC-F vaccine can induce specific immunity to radioresistant populations of mammary tumor cells and, thus, can complement radiotherapy, leading to synergistic killing.
Asunto(s)
Vacunas contra el Cáncer/administración & dosificación , Proteínas HSP70 de Choque Térmico/farmacología , Inmunoterapia/métodos , Neoplasias Mamarias Experimentales/radioterapia , Neoplasias Mamarias Experimentales/terapia , Tolerancia a Radiación , Animales , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/inmunología , Vacunas contra el Cáncer/inmunología , Fusión Celular , Proliferación Celular , Terapia Combinada , Células Dendríticas/metabolismo , Femenino , Proteínas HSP70 de Choque Térmico/administración & dosificación , Inmunidad Celular/inmunología , Inmunización , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/terapia , Activación de Linfocitos/inmunología , Virus del Tumor Mamario del Ratón/inmunología , Virus del Tumor Mamario del Ratón/efectos de la radiación , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Chaperonas Moleculares/inmunología , Radiación Ionizante , Infecciones por Retroviridae/inmunología , Infecciones por Retroviridae/radioterapia , Infecciones por Retroviridae/terapia , Infecciones Tumorales por Virus/inmunología , Infecciones Tumorales por Virus/radioterapia , Infecciones Tumorales por Virus/terapia , Vacunas Sintéticas/administración & dosificación , Vacunas Sintéticas/inmunologíaRESUMEN
Due to the relatively recent emergence of the human T-lymphotropic and the human immunodeficiency viruses, enthusiasm for the identification of novel viruses, especially retroviruses, with pathogenic potential in humans, remains high. Novel technologies are now available with the ability to search for unknown viruses, such as gene arrays and new generation sequencing of tissue and other samples. In 2006, chip technology identified a novel retrovirus in human prostate cancer (PCa) tissue samples. Due to close homology to a mouse retrovirus, the virus was named xenotropic murine leukaemia virus-related virus (XMRV). Ever since the initial disease association with PCa, XMRV has stirred a lot of attention and concern worldwide for the medical community, public health officials and in particular global transfusion services. Public response, in this new era of electronic communication and advocacy was rapid, wide and unprecedented. In this review, we outline the course of biomedical research efforts that were put forward internationally in the process of determining the risk to the human population, the response of the blood banking community and review the current state of knowledge of xenotropic murine retroviruses. Although XMRV is no longer regarded as an infection of humans, a lesson was learnt in modern virology that holds deeper implications for biomedical research, particularly stem cell generation and transplantation practices.